title: Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan.
abstract: BACKGROUND
  Early diagnosis and effective treatment with an appropriate drug form the main components of the World Health Organization's strategy to reduce malaria related mortality. The few available drugs might be safeguarded if combined with artesunate. The addition of artesunate to a standard antimalarial treatment substantially reduces treatment failure, recrudescence and gametocyte carriage.
  
  
  METHODS
  During late 2004, the efficacy of artesunate (4 mg/kg. day, on days 0-2) plus sulfadoxine-pyrimethamine (25 mg/kg, on day 0) for the treatment of uncomplicated Plasmodium falciparum malaria was investigated in four sentinel areas in Sudan, with different malaria transmission (Damazin, Kassala, Kosti, and Malakal).
  
  
  RESULTS
  Two hundreds and sixty-nine patients completed the 28-day follow-up. On day one, 60 (22.3%) patients were febrile and 15 (5.5%) patients were parasitaemic. On day three, all the patients were afebrile and aparasitaemic. While two patients (0.7%, Kassala) showed late Clinical and Parasitological Failures, the rest (99.3%) of the patients demonstrated Adequate Clinical and Parasitological Response. A gametocytaemia were detected during the follow-up in one patient (0.37%, Kassala). Adverse drug effects were detected in 32 (11.9%) patients.
  
  
  CONCLUSIONS
  The study showed that AS plus SP is an effective, safe drug in the treatment of uncomplicated P. falciparum malaria in Sudan.
authors.affiliation: National Malaria Control, Ministry of Health, Khartoum, Sudan. sakinaba@hotmail.com
authors.forename: Sakina B
authors.initials: SB
authors.lastname: Elamin
authors.forename: Elfatih M
authors.initials: EM
authors.lastname: Malik
authors.forename: Tarig
authors.initials: T
authors.lastname: Abdelgadir
authors.forename: Ammar H
authors.initials: AH
authors.lastname: Khamiss
authors.forename: Mamoun M
authors.initials: MM
authors.lastname: Mohammed
authors.forename: Elderderi S
authors.initials: ES
authors.lastname: Ahmed
authors.forename: Ishag
authors.initials: I
authors.lastname: Adam
mesh_terms: D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D037621:Artemisinins / Q000008:administration & dosage / Q000627:therapeutic use*; D000077332:Artesunate; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D018571:Sentinel Surveillance; D012717:Sesquiterpenes / Q000008:administration & dosage / Q000627:therapeutic use*; D013397:Sudan; D013413:Sulfadoxine / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; D012717:Sesquiterpenes; C001205:fanasil, pyrimethamine drug combination; D000077332:Artesunate; D013413:Sulfadoxine; D011739:Pyrimethamine